Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

Grassi, E.; Zingaretti, C.; Petracci, E.; Corbelli, J.; Papiani, G.; Banchelli, I.; Valli, I.; Frassineti, G.L.; Passardi, A.; Di Bartolomeo, M.; Pietrantonio, F.; Gelsomino, F.; Carandina, I.; Banzi, M.; Martella, L.; Bonetti, A.V.; Boccaccino, A.; Molinari, C.; Marisi, G.; Ugolini, G.; Nanni, O.; Tamberi, S.

doi:10.1016/j.esmoop.2023.101824

Cited by 13 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pCR was achieved in 34.5% of cases. Of interest, 46 out of the 48 patients with available microsatellite status were MSS [43]. Lin et al investigated the activity of the anti-PD-1 Camrelizumab associated with CAPOX after SCRT in patients affected by LARC, regardless of the MS status.…”

Section: Mismatch Repair-proficient (Pmmr) or Microsatellite Stabilit...mentioning

confidence: 99%

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Sullo,

Passardi,

Gallio

et al. 2024

Preprint

View full text Add to dashboard Cite

Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, tumor distant recurrence remains a concern, prompting exploration of Total Neoadjuvant Therapy (TNT) as a comprehensive treatment strat-egy. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, potentially revolutionizing neoadjuvant regimens. Non-operative management (NOM) represents a viable alternative post-neoadjuvant therapy for selected patients achieving clinical complete response (cCR). Additionally, monitoring minimal residual disease (MRD) using circulating tumor DNA (ctDNA) emerges as a non-invasive method for treatment response assessment. This review synthesizes current evidence on TNT, ICIs, NOM and ctDNA, elucidating their implications for rectal cancer management and highlighting avenues for future research and clinical application.

show abstract

Section: Mismatch Repair-proficient (Pmmr) or Microsatellite Stabilit...mentioning

confidence: 99%

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Sullo,

Passardi,

Gallio

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…pCR was achieved in 34.5% of cases. Notably, 46 out of the 48 patients with available microsatellite status were MSS [43]. Lin et al investigated the activity of the anti-PD-1 Camrelizumab associated with CAPOX after SCRT in patients affected by LARC, regardless of the MS status.…”

Section: Mismatch Repair-proficient (Pmmr) or Microsatellite Stabilit...mentioning

confidence: 99%

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Sullo,

Passardi,

Gallio

et al. 2024

JCM

Self Cite

View full text Add to dashboard Cite

Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, distant tumor recurrence remains a concern, prompting the exploration of total neoadjuvant therapy (TNT) as a comprehensive treatment strategy. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, potentially revolutionizing neoadjuvant regimens. Nonoperative management (NOM) represents a viable alternative post-neoadjuvant therapy for selected patients achieving complete clinical response (cCR). Additionally, monitoring minimal residual disease (MRD) using circulating tumor DNA (ctDNA) emerges as a non-invasive method for the assessment of treatment response. This review synthesizes current evidence on TNT, ICIs, NOM, and ctDNA, elucidating their implications for rectal cancer management and highlighting avenues for future research and clinical application.

show abstract

Optimizing Rectal Cancer Treatment: A Path Towards Personalization

Romesser,

Cercek

2024

Annals of Oncology

View full text Add to dashboard Cite

Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

Cited by 13 publications

References 41 publications

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Optimizing Rectal Cancer Treatment: A Path Towards Personalization

Contact Info

Product

Resources

About